Back

Use of factor XI inhibitors compared with DOACs in atrial fibrillation and thromboembolism prevention: a systematic review and meta-analysis of randomized-controlled trials

30 August 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (2) - Antithrombotic pharmacotherapy Anticoagulants ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Luiza Filagrana

Rio Do Sul (Brazil)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Mr G. Arrighini (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Doctor G. Occhipinti (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Doctor M. Thungthienthong (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Doctor M. Galli (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (2) - Antithrombotic pharmacotherapy

The Event

Event poster

ESC Congress 2025

30 August 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Balancing safety and efficacy: Factor XIa inhibitors vs. DOACs in atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials
thumbnail
Congress Presentation
Factor XI inhibitors in early clinical trials: a meta-analysis
thumbnail
Congress Presentation
Safety and efficacy of factor XI/XIa inhibitors compared to factor Xa inhibitors for stroke prophylaxis in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources